Gries Financial LLC Takes $212,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Gries Financial LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel reports. The firm bought 637 shares of the company’s stock, valued at approximately $212,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. Iron Triangle Partners LP bought a new position in shares of Medpace during the 3rd quarter valued at approximately $64,371,000. Wellington Management Group LLP lifted its position in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. DF Dent & Co. Inc. lifted its position in Medpace by 189.9% during the third quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after purchasing an additional 105,659 shares during the last quarter. Argent Capital Management LLC grew its stake in shares of Medpace by 431.5% in the 3rd quarter. Argent Capital Management LLC now owns 91,732 shares of the company’s stock worth $30,620,000 after buying an additional 74,473 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Medpace in the 3rd quarter worth about $23,321,000. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 2.0 %

NASDAQ MEDP opened at $350.04 on Friday. The stock has a market cap of $10.88 billion, a PE ratio of 30.65, a PEG ratio of 1.77 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $286.76 and a 12 month high of $459.77. The company’s 50-day moving average price is $342.11 and its 200-day moving average price is $353.38.

Analyst Upgrades and Downgrades

Several research analysts recently commented on MEDP shares. Redburn Atlantic began coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Truist Financial decreased their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.